Skip to content

Application and clinical trial of nanosheets in luminal cancer

Application and clinical trial of nanosheets in luminal cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065010
Enrollment
Unknown
Registered
2022-10-25
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

luminal cancer

Interventions

LDH/EDTA:tract perfusion

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: Advanced luminal cancer, and tumors grow within the lumen, and lost chance of surgery; Luminal cancer with recurrence and metastasis, and obstruction resulted from tumor blockage; Patients with no response to chemotherapy and immunotherapy; Patients with clinically confirmed luminal cancer, including: bladder cancer, breast cancer, esophageal cancer, stomach cancer, ovarian cancer and cervical cancer; Above 18 years old; No serious heart, liver, kidney and other important organ diseases; Good compliance and willing to cooperate with sample collection.

Exclusion criteria

Exclusion criteria: Patients who have severe comorbidities, such as malnutrition, cachexia, ascites; Patients who have coagulopathy, and other blood diseases; Majority of tumors are invasive carcinoma; Patients with systemic metastasis; Pregnant or lactating women; Patient were also accompanied with multiple organ tumors or severe uncontrolled medical disease or acute infection; Patients dont understand the purpose of this study or dont agree with requirements for the study; Patients who lack of legal capacity or limitation of legal capacity; Patients who are not willing to cooperate in sample collection; Patients who have related medical history which could interfere results and increase risk of patients.

Design outcomes

Primary

MeasureTime frame
Blood RT;Liver function and renal function;Tumor markers detection;Computed tomography (CT);

Countries

China

Contacts

Public ContactHuanlong Qin
qinhuanlong@tongji.edu.cn18001763088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026